ES2130672T3 - Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes. - Google Patents

Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.

Info

Publication number
ES2130672T3
ES2130672T3 ES95937008T ES95937008T ES2130672T3 ES 2130672 T3 ES2130672 T3 ES 2130672T3 ES 95937008 T ES95937008 T ES 95937008T ES 95937008 T ES95937008 T ES 95937008T ES 2130672 T3 ES2130672 T3 ES 2130672T3
Authority
ES
Spain
Prior art keywords
peptides
autoantigen
seq
pct
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937008T
Other languages
English (en)
Inventor
Anna Maria Helena Boots
Gijsbertus Francisc Verheijden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2130672T3 publication Critical patent/ES2130672T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS PEPTIDOS DERIVADOS DEL AUTOANTIGENO HC GP-39, DICHOS PEPTIDOS COMPRENDIENDO AL MENOS UNA DE LAS SECUENCIAS DE AMINOACIDO FGRSFTLAS (N 1), FTLASSETG (N NTQ (N LAS T RESTRINGIDAS MHC CLASE II PRESENTES EN EL AUTOANTIGENO HC GP-39 EN CARTILAGO ARTICULAR. HC GP-39 Y DICHOS PEPTIDOS PUEDEN SER UTILIZADOS EN UN TRATAMIENTO ESPECIFICO ANTIGENO DE LA DESTRUCCION DEL CARTILAGO ARTICULAR EN ENFERMEDADES AUTOINMUNES PARA INDUCIR LA TOLERANCIA DEL SISTEMA INMUNE. EL AUTOANTIGENO HC GP-39 Y DICHOS PEPTIDOS SON TAMBIEN ADECUADOS PARA INDUCIR ARTRITIS EN ANIMALES NO HUMANOS, PREFERIBLEMENTE RATONES. LA INVENCION ADEMAS SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHO AUTOANTIGENO Y/O DICHOS PEPTIDOS, A UN METODO DE DIAGNOSTICO PARA LA DETECCION DE CELULAS T AUTOREACTIVAS EN UNA MUESTRA DE PRUEBA Y EQUIPOS DE PRUEBA PARA UTILIZAR EN DICHO METODO.
ES95937008T 1994-10-27 1995-10-25 Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes. Expired - Lifetime ES2130672T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP95200886 1995-04-07

Publications (1)

Publication Number Publication Date
ES2130672T3 true ES2130672T3 (es) 1999-07-01

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937008T Expired - Lifetime ES2130672T3 (es) 1994-10-27 1995-10-25 Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.

Country Status (24)

Country Link
US (1) US5736507A (es)
EP (1) EP0733065B1 (es)
JP (1) JP3755894B2 (es)
KR (1) KR100485979B1 (es)
CN (1) CN1161379C (es)
AT (1) ATE177756T1 (es)
AU (1) AU696827B2 (es)
BR (1) BR9506377A (es)
CA (1) CA2173874A1 (es)
DE (1) DE69508380T2 (es)
DK (1) DK0733065T3 (es)
ES (1) ES2130672T3 (es)
FI (1) FI118472B (es)
GR (1) GR3030296T3 (es)
HK (1) HK1002012A1 (es)
HU (1) HU218027B (es)
IL (1) IL115744A (es)
MX (1) MX9602495A (es)
NO (1) NO316703B1 (es)
NZ (1) NZ295659A (es)
PL (1) PL183761B1 (es)
RU (1) RU2178797C2 (es)
TR (1) TR199501326A2 (es)
WO (1) WO1996013517A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
CN1310724A (zh) * 1998-07-23 2001-08-29 阿克佐诺贝尔公司 用于自身免疫疾病的免疫疗法中的新型肽
WO2000004917A2 (en) * 1998-07-23 2000-02-03 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
MXPA02003520A (es) * 1999-10-18 2002-08-20 Akzo Nobel Nv Imitaciones de peptido y peptidos modificados para utilizarse en inmunoterapia.
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003009808A2 (en) 2001-07-24 2003-02-06 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
DK2190473T3 (da) 2007-08-15 2013-03-25 Circassia Ltd Peptid med reduceret dimerdannelse
WO2010018384A1 (en) * 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
PT2153841E (pt) 2008-08-15 2012-03-21 Circassia Ltd Vacina compreendendo péptidos amb a 1 para utilização no tratamento de alergia a ambrósia
US8753644B2 (en) 2009-02-05 2014-06-17 Circassia Limited Grass peptides for vaccine
HUE029150T2 (hu) * 2009-10-27 2017-02-28 Erytech Pharma Készítmény specifikus immuntolerancia indukálására
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
KR100485979B1 (ko) 2006-01-27
DE69508380D1 (de) 1999-04-22
PL183761B1 (pl) 2002-07-31
CN1168677A (zh) 1997-12-24
GR3030296T3 (en) 1999-09-30
HK1002012A1 (en) 1998-07-24
NO962695L (no) 1996-06-26
FI962619A0 (fi) 1996-06-25
AU696827B2 (en) 1998-09-17
HU9601401D0 (en) 1996-07-29
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
JPH09507861A (ja) 1997-08-12
KR960705848A (ko) 1996-11-08
WO1996013517A1 (en) 1996-05-09
CA2173874A1 (en) 1996-05-09
DE69508380T2 (de) 1999-09-09
FI118472B (fi) 2007-11-30
EP0733065A1 (en) 1996-09-25
RU2178797C2 (ru) 2002-01-27
NO316703B1 (no) 2004-04-13
TR199501326A2 (tr) 1996-06-21
IL115744A (en) 2000-07-16
AU3925295A (en) 1996-05-23
EP0733065B1 (en) 1999-03-17
NO962695D0 (no) 1996-06-26
MX9602495A (es) 1997-05-31
PL315198A1 (en) 1996-10-14
ATE177756T1 (de) 1999-04-15
US5736507A (en) 1998-04-07
JP3755894B2 (ja) 2006-03-15
HU218027B (hu) 2000-05-28
NZ295659A (en) 1998-02-26
DK0733065T3 (da) 1999-10-11
FI962619A (fi) 1996-06-25
BR9506377A (pt) 1997-09-16
CN1161379C (zh) 2004-08-11

Similar Documents

Publication Publication Date Title
ES2130672T3 (es) Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.
Shoenfeld et al. Mycobacteria and autoimmunity
Taneja et al. HLA class II transgenic mice as models of human diseases
ATE167062T1 (de) Verfahren zur anregung antigenspezifischer t- zelltoleranz
NO962426L (no) Spermieantigen som tilsvarer et spermie zonabindende protein autoantigenepitop
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
Monneaux et al. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins
NZ332427A (en) Peptides suitable for use in antigen specific immunosuppressive therapy
ATE248602T1 (de) Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
ATE185151T1 (de) Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten
Choudhury et al. Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
Buus et al. The Interaction between MHC Class II Molecules and Immunogenic Peptides
Kennedy THE ROLE OF THE RT6 ALLOANTIGEN IN THE INDUCTION AND REGULATION OF TUBERCULIN DELAYED HYPERSENSITIVITY IN RATS (T-LYMPHOCYTES, SUBPOPULATIONS)
Anita Investigation of possible immunological mechanisms in the pathogenesis of a murine model of rheumatoid arthritis
Bach GAD Peptide VaccinesforT1DM: Not Just a Blueprint?
Houssiau Systemic lupus: From the bedside to the laboratory bench
Qian et al. of March 2, 2014.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 733065

Country of ref document: ES